Will WuXi Benefit From Rival ShangPharma Going Private?
This article was originally published in PharmAsia News
Executive Summary
China’s second largest CRO ShangPharma is likely to go private after a proposal from its founder, and some say the exit may also help its larger rival WuXi PharmaTech.